cibenzoline

Cibenzoline is a small molecule antiarrhythmic drug classified as a Class Ia agent. It acts primarily by blocking sodium channels in cardiac myocytes, thereby suppressing abnormal myocardial excitation and controlling irregular heart rhythms. In addition to its main Class I activity, cibenzoline exhibits limited Class III (potassium channel blockade) and Class IV (calcium channel blockade) effects[1][7]. Its mechanism of action includes reducing left ventricular pressure gradient (LVPG), mainly through decreased myocardial contractility[3][5]. Unlike some other antiarrhythmics such as disopyramide, cibenzoline has minimal anticholinergic side effects[5][6]. The drug is used for the treatment of tachyarrhythmias—including both ventricular and supraventricular arrhythmias—and has demonstrated efficacy in patients with hypertrophic obstructive cardiomyopathy (HOCM)[2][3][5]. It can be administered orally or intravenously and is typically dosed twice daily due to its elimination half-life of 8–12 hours[1].

Brand names

CibenzolineCibenzoline succinateCIBENZOLINE SUCCINATE TABLETS 100mg "TOWA"

Other names

cifenline